Cyclization strategies of meditopes: affinity and diffraction studies of meditope–Fab complexes

K. Bzymek,Yuelong Ma,Kendra A. Avery,D. Horne,John C. Williams

DOI: https://doi.org/10.1107/S2053230X16007202

2016-05-23

Acta Crystallographica Section F Structural Biology Communications

Abstract:An overview of cyclization strategies of a Fab-binding peptide to maximize affinity.

What problem does this paper attempt to address?

[Protective effects of extract of Ginkgo biloba on adriamycin-induced heart failure and its mechanism: role of ghrelin peptide]

Zhiwei Xu,Weikang Wu,Taohua Lan,Xuanhong Zhang

Abstract:Objective: To explore the protective effects of extract of Ginkgo biloba (EGB) in adriamycin (ADR)-induced heart failure (HF) and the mechanism of ghrelin peptide. Method: Wistar rats were randomly divided into three groups: control group, HF group and EGB group. ADR was injected in the rats of HF group and EGB group by caudal vein. After the last injection, the rats in EGB group were given intra-gastric administration of EGB solution (100 mg x kg(-1) x d(-1)). Three weeks later, cardiac function was detected; Ghrelin levels in plasma and myocardium were measured by radio-immunology assay (RIA); High energy phosphates (HEP) contents in myocardium were measured by HPLC; Myocardial gene expression of ghrelin was measured by RT-PCR. Result: Compared with control group, HF group had obviously decreased index of cardiac function, and these indexes such as +/- dp/dt max in EGB group were higher than those in ADR group. Plasma ghrelin level in HF group was higher than that in control group while myocardial ghrelin level was significantly lower than that in control group. Myocardial ATP content and gene expression of ghrelin mRNA in HF group were significantly lower than those in control group; Plasma ghrelin level in EGB group was significantly increased. Myocardial ATP content and gene expression of ghrelin mRNA in EGB group were significantly higher than those in HF group, and were closed to those of control group. Conclusion: Myocardial energy dysfunction is an important reason of ADR-induced HF. EGB therapy can improve cardiac function and energy metabolism in HF rats, partly because it might increase the expression and production of ghrelin, which can promote positive energy metabolism.
Effect of Ghrelin on Energy Metabolism in Chronic Heart Failure

Chaoshu Tang

2011-01-01

Abstract:Ghrelin stimulates appetite and weight gain,inducing obesity through a growth hormone-independent mechanism.It is involved in glucose and fat metabolism.Ghrelin could improve cardiac function and disturbed energy metabolism through inhibiting the production of inflammatory factors and myocardial remodeling in cachectic patients with chronic heart failure.Therefore,ghrelin plays an important role in maintaining homeostasis of myocardial energy metabolism in cachectic patients with chronic heart failure.With the beneficial effects of ghrelin on reversing myocardial remodeling,it may be a new therapeutic strategy for cachectic patients with end-stage heart failure.As a monitoring index,ghrelin might aid in the evaluation of the severity of the disease and patient prognosis.
The Treatment of Ghrelin on Cardiac Cachexia in Congestive Heart Failure

XU Jian-ping,LIU Yang,HE Ge,YANG Bao-yan,YANG Bao-wei,TANG Chao-shu

2012-01-01

Abstract:Ghrelin can promote growth-hormone releasing,vascular relaxing and lower blood pressure to improve heart performance.Ghrelin can also increase appetite,gain body weight and involve in regulating the metabolism of glucose and fat as well.Ghrelin can improve the function of blood vessel endothelium,inhibit inflammatory cell factor and myocardial hypertrophy so as to prevent myocardial remodeling.As an endogenous protective factor against myocardial damage,Ghrelin,by various mechanisms,can improve cardiac function in heart failure and cause positive energy balance,resulting in attenuating the development of cardiac cachexia in chronic heart failure.With its beneficial effect in against metabolic remodeling,Ghrelin may be a potential therapeutic approach to cachectic heart failure.As a monitoring index,Ghrelin may be used in evaluating the severity of heart failure and prognosis of the patients with heart failure.
Ghrelin Improves Disturbed Myocardial Energy Metabolism in Rats with Heart Failure Induced by Isoproterenol

Jian-Ping Xu,Hong-Xia Wang,Wen Wang,Li-Ke Zhang,Chao-Shu Tang

DOI: https://doi.org/10.1002/psc.1253

2010-01-01

Journal of Peptide Science

Abstract:To explore the effects of ghrelin on disturbed myocardial energy metabolism during chronic heart failure (CHF). Rats were subcutaneously injected with isoproterenol (ISO) for 10 days with or without ghrelin for another 10 days. Enzyme immunoassay was to measure ghrelin concentrations. Compared with the control group, ISO-treated rats showed suppressed cardiac function with high ghrelin/GHS-R expressions. These rats also showed the decreases in food consumption and weight. The decreased levels of plasma glucose and myocardial glucogen, but the high lactate in blood and myocardium showed myocardial metabolic disturbance. Compared with the group given ISO alone, the rats with ghrelin (20 and 100 mu g/kg/day) improved cardiac dysfunction and increased food intake by 13.5 and 14.2% (both P < 0.01), and rate of weight gain by 95% (P < 0.05) and 1.71-fold (P < 0.01), respectively. The plasma glucose were increased by 49.7 and 50.8% (both P < 0.01), and myocardial glucogen, by 40.5 and 51.7% (both P < 0.01), but blood lactate decreased by 1.56- and 1.96-fold (both P < 0.01), and myocardial lactate by 32.1 and 48.7% (both P < 0.05), respectively. Their MCT1 mRNA and protein expressions increased. The myocardial ghrelin/GHS-R pathway can be upregulated during CHF. The ghrelin can attenuate cardiac dysfunction and energy metabolic disturbance in CHF rats. Copyright (C) 2010 European Peptide Society and John Wiley & Sons, Ltd.
Endogenous Ghrelin Attenuates Pressure Overload-Induced Cardiac Hypertrophy Via A Cholinergic Anti-Inflammatory Pathway

Yuanjie Mao,Takeshi Tokudome,Ichiro Kishimoto,Kentaro Otani,Hirohito Nishimura,Osamu Yamaguchi,Kinya Otsu,Mikiya Miyazato,Kenji Kangawa

DOI: https://doi.org/10.1161/hypertensionaha.114.04864

IF: 9.8968

2015-01-01

Hypertension

Abstract:Cardiac hypertrophy, which is commonly caused by hypertension, is a major risk factor for heart failure and sudden death. Endogenous ghrelin has been shown to exert a beneficial effect on cardiac dysfunction and postinfarction remodeling via modulation of the autonomic nervous system. However, ghrelin’s ability to attenuate cardiac hypertrophy and its potential mechanism of action are unknown. In this study, cardiac hypertrophy was induced by transverse aortic constriction in ghrelin knockout mice and their wild-type littermates. After 12 weeks, the ghrelin knockout mice showed significantly increased cardiac hypertrophy compared with wild-type mice, as evidenced by their significantly greater heart weight/tibial length ratios (9.2±1.9 versus 7.9±0.8 mg/mm), left ventricular anterior wall thickness (1.3±0.2 versus 1.0±0.2 mm), and posterior wall thickness (1.1±0.3 versus 0.9±0.1 mm). Furthermore, compared with wild-type mice, ghrelin knockout mice showed suppression of the cholinergic anti-inflammatory pathway, as indicated by reduced parasympathetic nerve activity and higher plasma interleukin-1β and interleukin-6 levels. The administration of either nicotine or ghrelin activated the cholinergic anti-inflammatory pathway and attenuated cardiac hypertrophy in ghrelin knockout mice. In conclusion, our results show that endogenous ghrelin plays a crucial role in the progression of pressure overload–induced cardiac hypertrophy via a mechanism that involves the activation of the cholinergic anti-inflammatory pathway.
Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms

Zhiwei Xu,Shiqing Lin,Weikang Wu,Hongmei Tan,Zhi Wang,Chao Cheng,Lihe Lu,Xuanhong Zhang

DOI: https://doi.org/10.1016/j.tox.2008.02.018

IF: 4.571

2008-05-21

Toxicology

Abstract:We had reported that increased levels of endogenous ghrelin during the progression of doxorubicin-induced cardiomyopathy and heart failure might provide a compensatory self-protective effect. We investigated which pathway(s) produced these protective effects in vitro. Primary cultured cardiomyocytes were induced with doxorubicin in the presence or absence of ghrelin or a tumor necrosis factor-alpha (TNF-alpha) antagonist (etanercept). Ghrelin up-regulated TNF-alpha in a time- and dose-dependent manner. It significantly reduced cell apoptosis and markers of oxidative stress, such as malondialdehyde (MDA) content and lactate dehydrogenase (LDH) activity; it also increased anti-oxidative enzyme activity such as superoxide dismutase (MnSOD) and catalase (CAT), retained mitochondrial membrane potential and energy metabolism compared with doxorubicin alone. Moreover, ghrelin increased mitochondrial anti-apoptosis related gene protein expression such as bcl-2 and MnSOD, reduced cytoplasmic cytochrome C (Cyt C) release and strengthened the activation of NF-kappaB. All these effects were abrogated by etanercept. This suggests ghrelin affects the TNF-alpha/NF-kappaB activation pathways, up-regulating TNF-alpha, to produce anti-oxidative and anti-apoptotic effects that protected cardiomyocytes from doxorubicin-induced cytotoxicity.
Ghrelin inhibited pressure overload-induced cardiac hypertrophy by promoting autophagy via CaMKK/AMPK signaling pathway

Weiwei Lu,Huaiqiu Cai,Yao Chen,Xiang Liao,Linshuang Zhang,Tongtong Ma,Hong Sun,Yongfen Qi

DOI: https://doi.org/10.1016/j.peptides.2020.170446

IF: 3.867

2021-01-01

Peptides

Abstract:Ghrelin, a novel gut hormone, has been shown to exert protective effects on cardiac dysfunction and remodeling. However, the underlying mechanisms of its protective effects remain unclear. Here, we investigated the effects of ghrelin on cardiac hypertrophy and explored the mechanisms involved. Ghrelin (30 mu g.kg(-1). day(-1)) was systemically administered to rats with cardiac hypertrophy induced by abdominal aortic constriction (AAC) by a mini-osmotic pump the next day after surgery continuously for 4 weeks. The AAC treated rats without ghrelin infusion showed decreased ghrelin content and expression of its receptors in the hearts. Exogenous ghrelin greatly attenuated cardiac hypertrophy as shown by heart weight to tibial length (HW/TL), hemodynamics, echocardiography, histological analyses, and expression of hypertrophic markers induced by AAC. This corresponded with decreased cardiac fibrosis and inflammation in the hearts of AAC rats treated with ghrelin. Moreover, ghrelin significantly increased the myocardial expression of autophagy markers, which was further confirmed in cultured cardiomyocytes. Concurrently, cardiomyocyte apoptosis in vivo and in vitro was ameliorated by ghrelin, which was reversed by inhibition of autophagy. The enhancement of autophagy and inhibition of apoptosis by ghrelin were eliminated on pretreatment with compound C, an AMP-activated protein kinase (AMPK) inhibitor. Furthermore, inhibition of Ca2+/Calmodulin-dependent protein kinase kinase (CaMKK), an upstream kinase of AMPK, made ghrelin fail to activate AMPK and simultaneously reversed ghrelin's promotion of autophagy. In conclusion, ghrelin could exert its cardioprotective effects on cardiac hypertrophy by promoting autophagy, possibly via CaMKK/AMPK signaling pathway.
Comparison of analysis techniques for the lattice Boltzmann method

A. Caiazzo,M. Junk,Martin Rheinländer

DOI: https://doi.org/10.1016/j.camwa.2009.02.011

2009-09-01

Abstract:
Viral and host strategies to take advantage of the innate immune response.

Yong Zhang,Michael E. Hinojosa,Noah Yoo,M. Holtzman

DOI: https://doi.org/10.1165/rcmb.2009-0213ED

IF: 7.748

2010-11-01

American Journal of Respiratory Cell and Molecular Biology

Abstract:The struggle between respiratory viruses and their hosts rages on. Any doubt of the importance of that battle is quickly quelled by the recent pandemic of swine flu attributable to H1N1-type influenza A virus (IAV), as well as the devastating outbreaks of avian flu (attributable to H5N1-type IAV) and severe acute respiratory syndrome (SARS) (attributable to SARS–corona virus). In addition to the viral influence on acute illness, we (and others) have presented a considerable amount of experimental evidence that respiratory viruses are responsible, at least in part, for the pathogenesis of chronic obstructive lung diseases such as asthma and chronic obstructive pulmonary disorder (1). In each instance, the severity of infection and the consequent impact of the virus on the host is likely dictated by the outcome of the chess game between the pathogen and the immune response. Thus, an understanding of the innate and adaptive immune responses to viruses (particularly respiratory viruses) remains an important public health issue, and one that can be addressed experimentally. In that regard, the article by Senft and colleagues in the April 2010 issue of the AJRCMB demonstrates once again how a common respiratory virus can resource its small genome to outwit the larger and more complex genomic repertoire of its human host (2). In particular, that report provides new evidence for how respiratory syncytial virus (RSV) can subvert the antiviral IFN signaling system in lung macrophages. The findings provide a timely opportunity to update in brief the critical roles of IFN signaling as well as cells of the innate immune system in the virus-versus-host struggle, and to describe how this information might translate into improvements in host defense and disease outcome.
Excessive sympathoactivation and deteriorated heart function after myocardial infarction in male ghrelin knockout mice.

Yuanjie Mao,Takeshi Tokudome,Kentaro Otani,Ichiro Kishimoto,Mikiya Miyazato,Kenji Kangawa

DOI: https://doi.org/10.1210/en.2012-2132

IF: 5.051

2013-01-01

Endocrinology

Abstract:We have previously demonstrated the protective role of endogenous ghrelin against malignant arrhythmias in the very acute phase of myocardial infarction (MI). However, the role of endogenous ghrelin in the chronic phase is unknown. Therefore, the aim of the current study was to focus on the effects of endogenous ghrelin on cardiac function and sympathetic activation after acute MI. In 46 ghrelin-knockout (KO) and 41 wild-type (WT) male mice, MI was produced by left coronary artery ligation. The mortality due to heart failure within 2 weeks was 0% in WT and 10.9% in KO (P < 0.05). At the end of this period, lung weight/tibial length, atrial natriuretic peptide and brain natriuretic peptide transcripts, end-systolic and end-diastolic volumes were all significantly greater in KO mice, whereas systolic function, represented by ejection fraction (16.4 +/- 4.7% vs 25.3 +/- 5.1%), end-systolic elastance, and preload-recruitable stroke work, was significantly inferior to that in WT mice (P < 0.05). Telemetry recording and heart rate variability analysis showed that KO mice had stronger sympathetic activation after MI than did WT mice. Metoprolol treatment and ghrelin treatment in KO mice prevented excessive sympathetic activation, decreased plasma epinephrine and norepinephrine levels, and improved heart function and survival rate after MI. Our data demonstrate that endogenous ghrelin plays a crucial role in protecting heart function and reducing mortality after myocardial infarction, and that these effects seem to be partly the result of sympathetic inhibition. (Endocrinology 154: 1854-1863, 2013)
Ghrelin Protects Heart Against ERS-induced Injury and Apoptosis by Activating AMP-activated Protein Kinase

Gai-Gai Zhang,Huai-Qiu Cai,Yan-Hui Li,Yu-Bin Sui,Jin-Sheng Zhang,Jin-Rui Chang,Ming Ning,Yang Wu,Chao-Shu Tang,Yong-Fen Qi,Xin-Hua Yin

DOI: https://doi.org/10.1016/j.peptides.2013.08.015

IF: 3.867

2013-01-01

Peptides

Abstract:Ghrelin, the endogenous ligand of growth hormone secretagogue receptor (GHS-R), is a cardioprotective peptide. In our previous work, we have revealed that ghrelin could protect heart against ischemia/reperfusion (I/R) injury by inhibiting endoplasmic reticulum stress (ERS), which contributes to many heart diseases. In current study, using both in vivo and in vitro models, we investigated how ghrelin inhibits myocardial ERS. In the in vivo rat heart injury model induced by isoproterenol (ISO), we found that exogenous ghrelin could alleviate heart dysfunction, reduce myocardial injury and apoptosis and inhibit the excessive myocardial ERS induced by ISO. More importantly, the activation of AMP-activated protein kinase (AMPK) was observed. To explore the role of AMPK activation in ERS inhibition by ghrelin, we set up two in vitro ERS models by exposing cultured rat cardiomyocytes to tunicamycin(Tm) or dithiothreitol (DTT). In both models, compared with Tm or DTT treatment alone, pre-incubation cardiomyocytes with ghrelin significantly activated AMPK, reversed the upregulation of the ERS markers, C/EBP-homologous protein (CHOP) and cleaved caspase-12, and reduced apoptosis of cardiomyocytes. Further, we found that the ERS inhibitory and anti-apoptotic actions induced by ghrelin were blocked by an AMPK inhibitor. To investigate how ghrelin activates AMPK, selective antagonist of GHS-R1a and inhibitor of Ca(2+)/Calmodulin-dependent protein kinase kinase (CaMKK) were added, respectively, before ghrelin pre-incubation, and we found that AMPK activation was prevented and the ERS inhibitory and anti-apoptotic actions of ghrelin were blocked. In conclusion, ghrelin could protect heart against ERS-induced injury and apoptosis, at least partially through a GHS-R1a/CaMKK/AMPK pathway.
The protective effect of Ghrelin peptide on doxorubicin hydrochloride induced heart failure in rats

Ying Peng,Ping Zhang,Pengtao Zou,Yuxuan Zhou,Liang Shao

DOI: https://doi.org/10.1186/s13019-024-02994-3

2024-09-04

Journal of Cardiothoracic Surgery

Abstract:To investigate the protective effect and mechanism of Ghrelin on Doxorubicin (Dox) hydrochloride induced heart failure (HF) and myocardial injury in rats.

surgery,cardiac & cardiovascular systems
Retracted: the Correlation Between Angiogenesis and Abnormal Expression of SERCA2a, Phospholamban and the Endothelin Pathway in Heart Failure, and Improvement by Puerarin

Hui He,Meng-Qiong Shi,Jun Yang,Xiaowei Zeng,Hong Qiao,Lidong Wu,LI Lian-da

DOI: https://doi.org/10.1002/ptr.2437

2008-01-01

Abstract:Emerging evidence indicates that angiogenesis may be a potential new target in treating heart failure (HF). It was hypothesized that a lack of angiogenesis would correlate with an abnormal expression of sarco/endoplasmic reticulum ATPase 2a (SERCA2a) and phospholamban (PLB), and the activated endothelin (ET) pathway and oxidative stress in HF. If this is the case, such normal changes could be reversed by puerarin. HF was produced by coronary artery ligation for 4 weeks in rats. The rats were divided into three groups: sham, HF untreated and HF + puerarin (120 mg/kg per day, i.p.). Hemodynamic and echocardiographic changes, angiogenesis, cardiac morphology, serum biochemistry, mRNA and proteins of the angiogenesis pathway, the ET pathway and redox were measured. In the HF rats, hemodynamic and echocardiographic abnormalities, cardiac remodeling and histological changes with features of cardiac failure were associated with a lack of the angiogenesis pathway, accompanied by oxidative stress, an up-regulated ET pathway and abnormal SERCA2a and PLB expressions in HF rats. Puerarin significantly promoted angiogenesis and reversed the above changes. In conclusion, the absence of the angiogenesis pathway correlated with abnormal expression of SERCA2a and PLB and an activated ET-ROS (reactive oxygen species) system in the affected myocardium. Puerarin promoted the angiogenesis pathway, improved myocardial microcirculation and down-regulated the ET system, resulting in a reversal of the abnormalities of expression of SERCA2a and PLB, and the cardiac performance in HF.
Plasma Ghrelin Concentrations in Patients with Coronary Artery Disease Correlates with Heart Function and Prognosis

褚松筠,丁文惠,李桂忠,庞永正,唐朝枢

DOI: https://doi.org/10.3969/j.issn.1009-0126.2011.11.012

2011-01-01

Abstract:Objective To explore plasma ghrelin concentrations in patients with coronary artery disease and to analyze the relationships with heart function and prognosis.Methods Eighty-three patients with coronary artery disease that admitted in our center were recruited in the study,including 31 cases of STEMI,31 cases of NSTE-ACS and 21 cases of SAP.Twenty-five healthy subjects were recruited as controls.Plasma ghrelin concentrations of patients within 1 week after admission were assayed with ELISA kit.Biochemical analysis,biomarkers of myocardial injury and indices of heart function were also measured.The subjects were followed up for new-onset cardiac events.Results Plasma ghrelin concentrations in patients with coronary artery disease were lower than those of healthy controls,though no significant difference was found between those of ACS and SAP.Plasma ghrelin levels of patients with STEMI elevated progressively after admission, but still lower than those of controls till day 7.Plasma ghrelin levels of patients with ACS correlated with peak value of biomarkers of myocardial injury.Ghrelin levels of patients with STEMI negatively correlated with LVEF.Patients that experienced new-onset cardiac dysfunction and died with follow up had significant higher levels of plasma ghrelin.Conclusion Low levels of plasma ghrelin may take part in the development of coronary atherosclerosis;the elevation of plasma ghrelin after acute coronary events reflected a compensatory mechanism,and suggested ghrelin as a cardiac protective factors has prognostic value.
Inhibition of Endoplasm Reticulum Stress by Ghrelin Protects Against Ischemia/reperfusion Injury in Rat Heart.

Gai-Gai Zhang,Xu Teng,Yue Liu,Yan Cai,Ye-Bo Zhou,Xiao-Hui Duan,Jun-Qiu Song,Yi Shi,Chao-Shu Tang,Xin-Hua Yin,Yong-Fen Qi

DOI: https://doi.org/10.1016/j.peptides.2009.03.024

IF: 3.867

2009-01-01

Peptides

Abstract:Ghrelin is a multi-functional polypeptide with cardiovascular protective effects. We aimed to explore whether the cardioprotective effect of ghrelin is mediated by inhibiting myocardial endoplasmic reticulum stress (ERS). A Langendorff model of isolated rat heart was used with ischemia/reperfusion (I/R; 40/120min). Cardiac function was monitored, and histomorphologic features, degree of myocardial injury, level of ERS markers, and number of apoptotic cardiomyocytes were determined. Compared with control group, the I/R group showed significantly decreased cardiac function, seriously damaged myocardial tissue, increased number of apoptotic cells, and overexpression of mRNA and protein of ERS markers. However, preadministration of ghrelin in vivo (10−8mol/kg, intraperitoneal injection, every 12h, twice in all) greatly ameliorated the damaged heart function, attenuated myocardial injury and apoptosis, and decreased the expression of ERS markers: it decreased the mRNA and protein levels of glucose-regulated protein78 (GRP78) and C/EBP homologous protein (CHOP), with reduced caspase-12 protein expression. Furthermore, in vitro, ghrelin directly inhibited the myocardial ERS response induced by tunicamycin or dithiothreitol in rat cardiac tissue. Ghrelin could protect the heart against I/R injury, at least in part, through inhibiting myocardial ERS.
Ghrelin and the cardiovascular system

Takeshi Tokudome,Ichiro Kishimoto,Mikiya Miyazato,Kenj Kangawa

DOI: https://doi.org/10.1159/000360593

Abstract:Ghrelin is a peptide that was originally isolated from the stomach. It exerts potent growth hormone (GH)-releasing and orexigenic activities. Several studies have highlighted the therapeutic benefits of ghrelin for the treatment of cardiovascular disease. In animal models of chronic heart failure, the administration of ghrelin improved cardiac function and remodeling; these findings were replicated in human patients with heart failure. Moreover, in an animal study, ghrelin administration effectively reduced pulmonary hypertension induced by chronic hypoxia. In addition, repeated administration of ghrelin to cachectic patients with chronic obstructive pulmonary disease had positive effects on overall body function, including muscle wasting, functional capacity and sympathetic activity. The administration of ghrelin early after myocardial infarction (MI) reduced fatal arrhythmia and related mortality. In ghrelin-deficient mice, both exogenous and endogenous ghrelin were protective against fatal arrhythmia and promoted remodeling after MI. Although the mechanisms underlying the effects of ghrelin on the cardiovascular system remain unclear, there are indications that its beneficial effects are mediated through both direct physiological actions, including increased GH levels, improved energy balance and direct actions on cardiovascular cells, and regulation of autonomic nervous system activity. Therefore, ghrelin is a promising novel therapeutic agent for cardiovascular disease.
Ghrelin ameliorates cardiac fibrosis after myocardial infarction by regulating the Nrf2/NADPH/ROS pathway

Qian Wang,Ai-Dong Liu,Tian-Shu Li,Qian Tang,Xian-Cheng Wang,Xue-Bin Chen,Ai-dong Liu,Tian-shu Li,Xian-cheng Wang,Xue-bin Chen

DOI: https://doi.org/10.1016/j.peptides.2021.170613

IF: 3.867

2021-10-01

Peptides

Abstract:To evaluate the role of ghrelin in cardiac fibrosis after myocardial infarction (MI) and to investigate the underlying mechanisms of ghrelin-regulated Nrf2/NADPH/ROS pathway-mediated cardioprotection, the profile of Nrf2, fibrosis markers, and oxidative stress markers were characterized in a rat model of MI and Angiotensin II (Ang II)-stimulated cardiac fibroblasts (CFs). The effects of ghrelin on cardiac function, fibrosis and oxidative stress were investigated after MI in vivo. The role of ghrelin in CF migration and proliferation was evaluated in Ang II-stimulated CFs in vitro. Inhibition of ghrelin receptors using the antagonist, D-Lys3-GHRP-6, in addition to ghrelin was employed in MI and CFs to investigate the direct effect of ghrelin on cardiac fibrosis. Loss function of Nrf2 in CFs was performed to investigate the effect of ghrelin-regulated Nrf2 on oxidative stress and cardiac fibrosis. Ghrelin improved the post-MI cardiac function and reduced cardiac fibrosis. This phenotype is associated with the upregulation of Nrf2 and downregulation of fibrotic proteins, NADPH oxidase and ROS production. In line with in vivo findings, ghrelin attenuated Ang II-stimulated CF migration, proliferation, and oxidative stress in vitro. Inhibition of the ghrelin receptor or knockdown of Nrf2 abolished the beneficial effects of ghrelin on MI or Ang II-stimulated cardiac fibroblasts. In conclusion, ghrelin ameliorates post-MI and Ang II-induced cardiac fibrosis by activating Nrf2, which in turn inhibits the NADPH/ROS pathway.

pharmacology & pharmacy,biochemistry & molecular biology,endocrinology & metabolism
High-Energy Phosphate Metabolism and Creatine Kinase in Failing Hearts - A New Porcine Model

Y Ye,GR Gong,K Ochiai,JB Liu,JY Zhang

DOI: https://doi.org/10.1161/01.cir.103.11.1570

IF: 37.8

2001-01-01

Circulation

Abstract:Background —This study aimed to create a pig model of heart failure secondary to severe aortic stenosis and to examine the relationship between the alterations in myocardial high-energy phosphate (HEP) metabolism and protein expression of creatine kinase (CK) isoforms. Methods and Results —Sixteen pigs with left ventricular hypertrophy (LVH) secondary to ascending aortic banding and 10 normal pigs (N) were studied. Myocardial protein levels of CK isoforms (Western blot), HEP levels, and CK kinetics ( 31 P MR spectroscopy) were measured under basal conditions. Nine of the 16 animals with LVH developed congestive heart failure (CHF), as evidenced by ascites (100 to 2000 mL). LV weight/body weight ratio (g/kg) was 2.18±0.15 in N hearts, 3.04±0.14 in hearts with LVH ( P <0.01), and 4.23±0.36 in hearts with CHF ( P <0.01 versus LVH). Right ventricle weight/body weight ratio and LV end-diastolic pressure were significantly higher in hearts with CHF (each P <0.01 versus N or LVH). Myocardial phosphocreatine/ATP ratios and the CK forward flux rates were decreased in LVH hearts, most severely in hearts with CHF. CK-M/β-actin ratios were 2.21±12 (N), 1.69±0.15 (LVH), and 1.39±0.27 (CHF, P <0.05 versus N). CK-mitochondria (CK-Mt)/β-actin ratios were 1.40±0.09 (N), 1.24±0.09 (LVH), and 1.02±0.08 (CHF, P <0.05 versus N or LVH). The severity of the reduction of CK flux rate was linearly related to the severity of the decrease of CK-Mt/β-actin ( r =0.68, P <0.01). Conclusions —In this new model of heart failure/hypertrophy, the abnormal myocardial HEP metabolism is related to the decreased CK-Mt protein level, which in turn is related to the severity of the hypertrophy.
CXCR-4 Is Expressed by Primary Macrophages and Supports CCR5-Independent Infection by Dual-Tropic but Not T-Tropic Isolates of Human Immunodeficiency Virus Type 1

Y. Yi,Shalini Rana,J. D. Turner,N. Gaddis,R. Collman

DOI: https://doi.org/10.1128/JVI.72.1.772-777.1998

IF: 6.549

1998-01-01

Journal of Virology

Abstract:ABSTRACT Primary macrophages are infected by macrophage (M)-tropic but not T-cell line (T)-tropic human immunodeficiency virus type 1 (HIV-1) strains, and CCR5 and CXCR-4 are the principal cofactors utilized for CD4-mediated entry by M-tropic and T-tropic isolates, respectively. Macrophages from individuals homozygous for an inactivating mutation of CCR5 are resistant to prototype M-tropic strains that depend on CCR5 but are permissive for a dual-tropic isolate, 89.6, that can use both CCR5 and CXCR-4, as well as CCR2b, CCR3, and CCR8. Here we show that 89.6 entry into CCR5-deficient macrophages is blocked by an anti-CXCR-4 antibody and by the CXCR-4-specific chemokine SDF but not by the ligands to CCR2b or CCR3. Reverse transcription-PCR demonstrated expression of CXCR-4 but not CCR3 or CCR8 in macrophages, while CCR2b was variable. Macrophage surface expression of CXCR-4 was confirmed by immunofluorescence staining and flow cytometry. Thus, CXCR-4 is expressed by primary macrophages and functions as a cofactor for entry by dual-tropic but not T-tropic HIV-1 isolates, and macrophage resistance to T-tropic strains does not result from a lack of the T-tropic entry cofactor CXCR-4. Since CXCR-4 on macrophages can be used by some but not other isolates, these results indicate that HIV-1 strains differ in how they utilize chemokine receptors as cofactors for entry and that the ability of a chemokine receptor to mediate HIV-1 entry differs, depending on the cell type in which it is expressed.
Ghrelin Reduces Rat Myocardial Calcification Induced by Nicotine and Vitamin D3 in Vivo.

Fei Wang,Tao Jiang,Chaoshu Tang,Zijie Su,Nong Zhang,Guizhong Li

DOI: https://doi.org/10.3892/ijmm.2011.710

IF: 5.314

2011-01-01

International Journal of Molecular Medicine

Abstract:Ghrelin, a newly discovered bioactive peptide, initially was identified as a strong stimulant for the release of growth hormone (GH) and that has improved cardiac function in patients suffering from end-stage chronic heart failure. Increasing evidence has demonstrated that ghrelin may have myocardial protective effects. However, the role of ghrelin in the pathogenesis of cardiovascular diseases remains unclear. In this study, an in vivo model of rat myocardial calcification induced by vitamin D3 and nicotine was used to study the possible mechanism in the regulatory action of ghrelin on the calcified myocardium. Calcification increased total Ca2+ content and 45Ca2+ deposition in the myocardium and alkaline phosphatase (ALP) activation in the plasma. Compared with the control group, ghrelin mRNA expression was up-regulated and the myocardium calcium content was significantly increased in vitamin D3 and nicotine-treated rats. Rats were subcutaneously injected with 1 or 10 nmol/kg ghrelin. Rats treated with both low- and high-dose ghrelin decreased total Ca2+ content and 45Ca2+ deposition in cardiac muscle and inhibited ALP activation in the myocardium and plasma, in a concentration-dependent manner. In addition, osteopontin (OPN) mRNA expression significantly decreased and that of endothelin (ET-1) significantly increased with myocardial calcification. Ghrelin treatment increased OPN expression at the mRNA level and reduced ET-1 mRNA expression in a dose-dependent manner. These results indicate that exogenous administration with ghrelin attenuates myocardial calcification induced by nicotine and vitamin D3, and that the possible mechanism is via the ghrelin-induced increase in the OPN mRNA levels and decrease in the ET-1 mRNA expression in the myocardium.

Cyclization strategies of meditopes: affinity and diffraction studies of meditope–Fab complexes

[Protective effects of extract of Ginkgo biloba on adriamycin-induced heart failure and its mechanism: role of ghrelin peptide]

Effect of Ghrelin on Energy Metabolism in Chronic Heart Failure

The Treatment of Ghrelin on Cardiac Cachexia in Congestive Heart Failure

Ghrelin Improves Disturbed Myocardial Energy Metabolism in Rats with Heart Failure Induced by Isoproterenol

Endogenous Ghrelin Attenuates Pressure Overload-Induced Cardiac Hypertrophy Via A Cholinergic Anti-Inflammatory Pathway

Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms

Ghrelin inhibited pressure overload-induced cardiac hypertrophy by promoting autophagy via CaMKK/AMPK signaling pathway

Comparison of analysis techniques for the lattice Boltzmann method

Viral and host strategies to take advantage of the innate immune response.

Excessive sympathoactivation and deteriorated heart function after myocardial infarction in male ghrelin knockout mice.

Ghrelin Protects Heart Against ERS-induced Injury and Apoptosis by Activating AMP-activated Protein Kinase

The protective effect of Ghrelin peptide on doxorubicin hydrochloride induced heart failure in rats

Retracted: the Correlation Between Angiogenesis and Abnormal Expression of SERCA2a, Phospholamban and the Endothelin Pathway in Heart Failure, and Improvement by Puerarin

Plasma Ghrelin Concentrations in Patients with Coronary Artery Disease Correlates with Heart Function and Prognosis

Inhibition of Endoplasm Reticulum Stress by Ghrelin Protects Against Ischemia/reperfusion Injury in Rat Heart.

Ghrelin and the cardiovascular system

Ghrelin ameliorates cardiac fibrosis after myocardial infarction by regulating the Nrf2/NADPH/ROS pathway

High-Energy Phosphate Metabolism and Creatine Kinase in Failing Hearts - A New Porcine Model

CXCR-4 Is Expressed by Primary Macrophages and Supports CCR5-Independent Infection by Dual-Tropic but Not T-Tropic Isolates of Human Immunodeficiency Virus Type 1

Ghrelin Reduces Rat Myocardial Calcification Induced by Nicotine and Vitamin D3 in Vivo.